Does Tissue Factor Participate In Angiogenesis?

A Bierhaus,Ym Zhang,R Ziegler,Pp Nawroth

1998-01-01

Abstract:Over recent decades tissue factor, the high-affinity surface receptor and cofactor for plasma factor VII/VIIa, has been generally viewed as the primary cellular initiator of the extrinsic coagulation cascade. Recent studies, however, implicate that there might be a role for tissue factor beyond hemostasis.

What problem does this paper attempt to address?

Tissue factor (:Factor VIIa) in the heart and vasculature: More than an envelope

E D'Alessandro,J J N Posma,H M H Spronk,H Ten Cate

DOI: https://doi.org/10.1016/j.thromres.2018.06.020

Abstract:Blood coagulation comprises a complex cellular and molecular mechanism that maintains vascular integrity, protects against bleeding (hemostasis) and responds to injury. However, several elements of the coagulation system, including several coagulation factors and platelets, are also involved in other physiological and pathological processes. Tissue factor (TF) is a cell surface glycoprotein expressed in a vast variety of cell types and essential for hemostasis. Upon exposure of the TF-rich subendothelium to the blood stream, Factor VII (FVII) can bind to TF. TF subsequently facilitates the activation of FVII into activated FVII (FVIIa) thereby initiating the extrinsic coagulation pathway followed by the activation of FX and thrombin formation. Besides its hemostatic role in the vasculature, the TF:FVIIa pathway is active in many other compartments and organs where it can take part and mediate different physiological and pathological processes. The so-called non-hemostatic functions of TF:VIIa play a role in diverse processes such as inflammation, atherosclerosis and vascular and cardiac remodeling. This narrative review aims to reassess the most important and recent findings regarding the complex signaling pathways initiated by the TF:FVIIa complex, with an emphasis on the heart and blood vessels. Understanding how the mechanisms of TF:FVIIa signaling contribute to both physiological and pathological processes, is one of the keys to the development of new treatment strategies in cardiovascular disease.
Structure–Function Relationship of the Interaction between Tissue Factor and Factor VIIa

Joshua M Gajsiewicz,James H Morrissey,Joshua Gajsiewicz,James Morrissey

DOI: https://doi.org/10.1055/s-0035-1564044

2015-09-26

Seminars in Thrombosis and Hemostasis

Abstract:Interactions between tissue factor and factor VIIa are the primary initiators of coagulation in hemostasis and certain thrombotic diseases. Tissue factor, an integral membrane protein expressed extensively outside of the vasculature, is the regulatory protein cofactor for coagulation factor VIIa. Factor VIIa, a trypsin-like serine protease homologous with other blood coagulation proteases, is weakly active when free in solution and must bind its membrane-bound cofactor for physiologically relevant activity. Tissue factor allosterically activates factor VIIa by several mechanisms such as active site positioning, spatial stabilization, and direct interactions with the substrate. Protein-membrane interactions between tissue factor, factor VIIa, and substrates all play critical roles in modulating the activity of this enzyme complex. Additionally, divalent cations such as Ca(2+) and Mg(2+) are critical for correct protein folding, as well as protein-membrane and protein-protein interactions. The contributions of these factors toward tissue factor-factor VIIa activity are discussed in this review.

peripheral vascular disease,hematology
Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis

Mikael Åberg,Oskar Eriksson,Agneta Siegbahn

DOI: https://doi.org/10.1055/s-0035-1564046

2015-09-29

Seminars in Thrombosis and Hemostasis

Abstract:Tissue factor (TF) is a 47-kDa transmembrane glycoprotein and the main initiator of the blood coagulation cascade. Binding to its ligand factor VIIa (FVIIa) also initiates noncoagulant signaling with broad biological implications. In this review, we discuss how TF interacts with other cell-surface proteins, which affect biological functions such as cell migration and cell survival. A vast number of publications have demonstrated the importance of TF-induced activation of protease-activated receptors, but recently published research has indicated a more complicated picture. As it has been discovered that TF interacts with integrins and receptor tyrosine kinases, novel signaling mechanisms for the TF/FVIIa complex have been presented. The knowledge of these new aspects of TF signaling may, for instance, facilitate the development of new treatment strategies for cancer and acute coronary syndromes, two examples of diseases characterized by aberrant TF expression and signaling.

peripheral vascular disease,hematology
Tissue factor pathway inhibitor – cofactor-dependent regulation of the initiation of coagulation

Josefin Ahnström,Anastasis Petri,James T.B. Crawley

DOI: https://doi.org/10.1097/moh.0000000000000838

2024-09-27

Current Opinion in Hematology

Abstract:Haemostasis corresponds to the cellular and biochemical processes that limits bleeding following blood vessel damage. To be effective, the haemostatic response at the site of vessel injury must be rapid but also highly controlled to specifically localize clot formation – both spatially and temporally. Haemostasis is, therefore, finely balanced by highly orchestrated procoagulant and anticoagulant mechanisms. Tissue factor (TF) initiated coagulation is the major mechanism that initiates thrombin generation after vascular injury. TF is a transmembrane glycoprotein expressed on the surface of various cells, particularly those surrounding blood vessels. When vascular integrity is compromised, TF is exposed to circulating plasma activated factor VII (FVIIa). TF binding allosterically activates FVIIa enabling it to proteolytically activate factor X (FX) to factor Xa (FXa) and factor IX to activated factor IX – together these steps correspond to the initiation phase of coagulation. FXa inefficiently converts small amounts of prothrombin to thrombin. Thrombin activates platelets and other coagulation procofactors, including factor VIII (FVIII) and factor V (FV). FVIIIa forms the tenase complex with activated factor IX to amplify FXa generation. After activation, FXa is released and incorporated into the prothrombinase complex together with FVa, resulting in a strong enhancement of thrombin generation and the start of the propagation phase of coagulation. Locally generated thrombin can then proteolytically convert fibrinogen into fibrin, which polymerizes to stabilize the haemostatic plug [1] .

hematology
Tissue Factor and Tissue Factor Pathway Inhibitor in Coronary Atherosclerotic Plaque

ZHU Ying,LUO Xin-ping,MA Duan

DOI: https://doi.org/10.3969/j.issn.1004-3934.2007.05.030

2007-01-01

Abstract:Tissue factor(TF) is a receptor for factor FVII/FVIIa on a cell surface.It is an important initiator of the exdogenous coagulation cascade,and TF activates exdogenous coagulation cascade and causes thrombosis.Human tissue factor pathway inhibitor(TFPI) is a member of the Kunitz-type serine protease inhibitor family,which is divided into TFPI-1 and TFPI-2.The key function of TFPI-1 is anti-coagulation,while TFPI-2 as a broad-spectrum serine protease inhibitor can function as an MMP inhibitor.The differences between TFPI-1 and TFPI-2 lead to discrepancies in the roles they play in a variety of pathological processes in coronary atherosclerotic plaque.This article reviews recent progress in the related research.
[Tissue factor in acute coronary syndromes]

B A Steppich,I Ott

Abstract:Rupture of an atherosclerotic plaque with subsequent thrombosis and myocardial ischemia is the patho-physiological mechanism in acute coronary syndromes. Tissue factor (TF) as the main initiator of the extrinsic coagulation cascade plays a central role in the pathogenesis of acute coronary syndromes. The extent of the thrombotic process is modulated by local vascular TF of the ruptured plaque as well as by circulating TF. In addition, TF alters signaling pathways and, thereby, contributes to inflammatory reactions and vascular remodeling. This review addresses current concepts of the role of TF in acute coronary syndromes and discusses potential consequences and therapeutic approaches.
Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets

Ingrid Müller,Antje Klocke,Meike Alex,Matthias Kotzsch,Thomas Luther,Eberhard Morgenstern,Susanne Zieseniss,Stefan Zahler,Klaus Preissner,Bernd Engelmann

DOI: https://doi.org/10.1096/fj.02-0574fje

2003-01-02

The FASEB Journal

Abstract:Although tissue factor (TF), the principial initiator of physiological coagulation and pathological thrombosis, has recently been proposed to be present in human blood, the functional significance and location of the intravascular TF is unknown. In the plasma portion of blood, we found TF to be mainly associated with circulating microvesicles. By cell sorting with the specific marker CD42b, platelet-derived microvesicles were identified as a major location of the plasma TF. This was confirmed by the presence of full-length TF in microvesicles acutely shedded from the activated platelets. TF was observed to be stored in the alpha-granules and the open canalicular system of resting platelets and to be exposed on the cell surface after platelet activation. Functional competence of the blood-based TF was enabled when the microvesicles and platelets adhered to neutrophils, as mediated by P-selectin and neutrophil counterreceptor (PSGL-1, CD18 integrins) interactions. Moreover, neutrophil-secreted oxygen radical species supported the intravascular TF activity. The pools of platelet and microvesicle TF contributed additively and to a comparable extent to the overall blood TF activity, indicating a substantial participation of the microvesicle TF. Our results introduce a new concept of TF-mediated coagulation crucially dependent on TF associated with microvesicles and activated platelets, which principally enables the entire coagulation system to proceed on a restricted cell surface.

cell biology,biochemistry & molecular biology,biology
The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans

Nourhan Hassan,Janes Efing,Ludwig Kiesel,Gerd Bendas,Martin Götte

DOI: https://doi.org/10.3390/cancers15051524

2023-03-01

Cancers

Abstract:Historically, the only focus on tissue factor (TF) in clinical pathophysiology has been on its function as the initiation of the extrinsic coagulation cascade. This obsolete vessel-wall TF dogma is now being challenged by the findings that TF circulates throughout the body as a soluble form, a cell-associated protein, and a binding microparticle. Furthermore, it has been observed that TF is expressed by various cell types, including T-lymphocytes and platelets, and that certain pathological situations, such as chronic and acute inflammatory states, and cancer, may increase its expression and activity. Transmembrane G protein-coupled protease-activated receptors can be proteolytically cleaved by the TF:FVIIa complex that develops when TF binds to Factor VII (PARs). The TF:FVIIa complex can activate integrins, receptor tyrosine kinases (RTKs), and PARs in addition to PARs. Cancer cells use these signaling pathways to promote cell division, angiogenesis, metastasis, and the maintenance of cancer stem-like cells. Proteoglycans play a crucial role in the biochemical and mechanical properties of the cellular extracellular matrix, where they control cellular behavior via interacting with transmembrane receptors. For TFPI.fXa complexes, heparan sulfate proteoglycans (HSPGs) may serve as the primary receptor for uptake and degradation. The regulation of TF expression, TF signaling mechanisms, their pathogenic effects, and their therapeutic targeting in cancer are all covered in detail here.

oncology
Tissue factor at the crossroad of coagulation and cell signaling

H. Zelaya,A.S. Rothmeier,W. Ruf,A. S. Rothmeier

DOI: https://doi.org/10.1111/jth.14246

2018-08-16

Journal of Thrombosis and Haemostasis

Abstract:The tissue factor (TF) pathway plays a central role in hemostasis and thrombo-inflammatory diseases. Although structure-function relationships of the TF initiation complex are elucidated, new facets of the dynamic regulation of TF's activities in cells continue to emerge. Cellular pathways that render TF non-coagulant participate in signaling of distinct TF complexes with associated proteases through the protease-activated receptor (PAR) family of G protein-coupled receptors. Additional co-receptors, including the endothelial protein C receptor (EPCR) and integrins, confer signaling specificity by directing subcellular localization and trafficking. We here review how TF is switched between its role in coagulation and cell signaling through thiol-disulfide exchange reactions in the context of physiologically relevant lipid microdomains. Inflammatory mediators, including reactive oxygen species, activators of the inflammasome, and the complement cascade play pivotal roles in TF procoagulant activation on monocytes, macrophages and endothelial cells. We furthermore discuss how TF, intracellular ligands, co-receptors and associated proteases are integrated in PAR-dependent cell signaling pathways controlling innate immunity, cancer and metabolic inflammation. Knowledge of the precise interactions of TF in coagulation and cell signaling is important for understanding effects of new anticoagulants beyond thrombosis and identification of new applications of these drugs for potential additional therapeutic benefits.

peripheral vascular disease,hematology
Tissue factor in atherosclerosis and atherothrombosis

Steven P Grover,Nigel Mackman

DOI: https://doi.org/10.1016/j.atherosclerosis.2020.06.003

IF: 5.3

Atherosclerosis

Abstract:Atherosclerosis is a chronic inflammatory disease that is characterized by the formation of lipid rich plaques in the wall of medium to large sized arteries. Atherothrombosis represents the terminal manifestation of this pathology in which atherosclerotic plaque rupture or erosion triggers the formation of occlusive thrombi. Occlusion of arteries and resultant tissue ischemia in the heart and brain causes myocardial infarction and stroke, respectively. Tissue factor (TF) is the receptor for the coagulation protease factor VIIa, and formation of the TF:factor VIIa complex triggers blood coagulation. TF is expressed at high levels in atherosclerotic plaques by both macrophage-derived foam cells and vascular smooth muscle cells, as well as extracellular vesicles derived from these cells. Importantly, TF mediated activation of coagulation is critically important for arterial thrombosis in the setting of atherosclerotic disease. The major endogenous inhibitor of the TF:factor VIIa complex is TF pathway inhibitor 1 (TFPI-1), which is also present in atherosclerotic plaques. In mouse models, increased or decreased expression of TFPI-1 has been found to alter atherosclerosis. This review highlights the contribution of TF-dependent activation of coagulation to atherthrombotic disease.
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy

Zhiwei Hu,Jijun Cheng,Jie Xu,Wolfram Ruf,Charles J. Lockwood

DOI: https://doi.org/10.1007/s10456-016-9530-9

IF: 10.658

2016-11-02

Angiogenesis

Abstract:Identification of target molecules specific for angiogenic vascular endothelial cells (VEC), the inner layer of pathological neovasculature, is critical for discovery and development of neovascular-targeting therapy for angiogenesis-dependent human diseases, notably cancer, macular degeneration and endometriosis, in which vascular endothelial growth factor (VEGF) plays a central pathophysiological role. Using VEGF-stimulated vascular endothelial cells (VECs) isolated from microvessels, venous and arterial blood vessels as in vitro angiogenic models and unstimulated VECs as a quiescent VEC model, we examined the expression of tissue factor (TF), a membrane-bound receptor on the angiogenic VEC models compared with quiescent VEC controls. We found that TF is specifically expressed on angiogenic VECs in a time-dependent manner in microvessels, venous and arterial vessels. TF-targeted therapeutic agents, including factor VII (fVII)-IgG1 Fc and fVII-conjugated photosensitizer, can selectively bind angiogenic VECs, but not the quiescent VECs. Moreover, fVII-targeted photodynamic therapy can selectively and completely eradicate angiogenic VECs. We conclude that TF is an angiogenic-specific receptor and the target molecule for fVII-targeted therapeutics. This study supports clinical trials of TF-targeted therapeutics for the treatment of angiogenesis-dependent diseases such as cancer, macular degeneration and endometriosis.

peripheral vascular disease
Activated Factor VII-Antithrombin Complex, a Biomarker of Tissue Factor-Related Pathways in Different Clinical Settings: A Narrative Review from Cardiovascular Diseases to Cancer

Sara Moruzzi,Annalisa Castagna,Marianna Spizzo,Silvia Udali,Patrizia Pattini,Francesca Pizzolo,Simonetta Friso,Nicola Martinelli

DOI: https://doi.org/10.3390/diagnostics14161711

2024-08-06

Abstract:Tissue factor (TF) is a transmembrane glycoprotein that represents the fundamental physiological initiator of the coagulation cascade through its interaction with factor VII. TF belongs to the cytokine receptor protein superfamily and contributes to the transduction of cellular signaling. Therefore, TF-related pathways are involved in multiple pathophysiological processes, not only in coagulation/thrombosis but in a wider mechanisms' panorama, ranging from infective to neoplastic diseases. Consistently, the measurement of TF activity could have a diagnostic and/or prognostic meaning in different clinical conditions. However, the transmembrane localization, the expression on different cellular types and circulating extracellular vesicles, and the different conformations (encrypted and decrypted) and variants (such as the soluble alternatively spliced TF) hamper TF assessment in clinical practice. The activated factor VII-antithrombin (FVIIa-AT) complex is proposed as an indirect biomarker of the TF-FVIIa interaction and, consequently, of the functionally active TF expression. In this narrative review, we evaluate the clinical studies investigating the role of plasma concentration of FVIIa-AT in health and disease. Although without conclusive data, high FVIIa-AT concentrations predict the worst clinical outcomes in different pathologic conditions, such as cardiovascular disease and cancer, thereby suggesting that overactivation of TF-related pathways may play an unfavorable role in various clinical settings.
Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?

Jan F. Vojacek

DOI: https://doi.org/10.1177/1076029616673733

2016-10-18

Clinical and Applied Thrombosis/Hemostasis

Abstract:Present review highlights some new aspects of the role of individual components of blood coagulation process and proposes a modified concept of hemocoagulation cascade. The role of FXII in the initiation of the so-called intrinsic coagulation system is currently questioned. Its role has been recently demonstrated mainly in the thrombus propagation and final stabilization together with factors XI and XIII. The edited concept underlines the common part of the tissue factor (TF) in the initiation of both the intrinsic and extrinsic pathways of the coagulation system and therefore may make it not improperly be called the TF coagulation pathway. The search for new antithrombotic agents shows that the level of the coagulation system blockade depends on which step in the coagulation cascade is targeted and results in different degrees of the antithrombotic efficiency and the risk of bleeding complications.
Formation Of Tissue Factor-Factor Viia-Factor Xa Complex Promotes Cellular Signaling And Migration Of Human Breast Cancer Cells

X Jiang,Ma Bailly,Ts Panetti,M Cappello,Wh Konigsberg,Me Bromberg

DOI: https://doi.org/10.1111/j.1538-7836.2004.00545.x

2004-01-01

Abstract:Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factor (F)VIIa. Recently, TF has been shown to promote cellular signaling. tumor growth, angiogenesis, and metastasis. In the present study, we examined the pathway by which TF-FVIIa complex induces cellular signaling in human breast cancer cells using the Adr-MCF-7 cell line. This cell line has high endogenous TF expression as measured by flow cytometry and expression of protease -activated receptors 1 and 2 (PAR1 and PAR2) as determined by reverse transcriptase-polymerase chain reaction analysis. Both PAR1 and PAR2 are functionally active as determined by induction of p44/42 mitogen-activated protein kinase (MAPK) phosphorylation using specific agonist peptides. We found that MAPK phosphorylation in this cell line was strongly induced by the combination of FVIIa and factor (F)X. but not by FVIIa alone at a concentration of FVIIa that approaches physiological levels. Induction of MAPK phosphorylation involved the formation of TF-FVIIa-FXa complex and occurred by a pathway that did not require thrombin formation, indicating a critical role for FXa generation. In addition, induction of MAPK phosphorylation was found to be independent of PAR I activation. We then examined whether TF-FVIIa complex formation could promote tumor cell migration using a modified Boyden chamber chemotaxis assay. The combination of FVIIa and FX, but not FVIIa alone, strongly induced migration of tumor cells by a pathway that probably involves PAR2, but not PAR1 activation. MAPK phosphorylation was found to be required for the induction of cell migration by the combination of FVIIa and FX. These data suggest that TF-FVIIa-mediated signaling in human breast cancer cells occurs most efficiently by formation of the TF-FVIIa-FXa complex. One of the physiological consequences of this signaling pathway is enhanced cell migration that is probably mediated by PAR2, but not PAR1 activation.
Progression of tissue factor in the malignant tumor

Yanlin Lu,Lihong Fan

DOI: https://doi.org/10.3969/j.issn.1672-4992.2015.05.39

2015-01-01

Journal of Modern Oncology

Abstract:Tissue factor conducts as cell surface receptor for coagulation factor Ⅶ to initiate extrinsic coagulation pathway,involving in tumor hypercoagulable state. Whatˊs more,it is highly expressed in multiple cancers,and medi-ates multiple signal transduction to affect tumor growth and metastasis.
Factor VII-Activating Protease: Hemostatic Protein or Immune Regulator?

Sacha Zeerleder

DOI: https://doi.org/10.1055/s-0037-1607431

2017-11-24

Seminars in Thrombosis and Hemostasis

Abstract:Abstract Factor VII (FVII)-activating protease (FSAP) is a serine protease in plasma, which was initially described to play a role in coagulation by activation of FVII, independent of tissue factor, and in fibrinolysis by cleavage of single-chain urokinase. Recent studies, however, suggest that FSAP-mediated FVII cleavage is negligible and that FSAP may exert procoagulant functions via cleavage of tissue factor pathway inhibitor. Meanwhile, many substrates of FSAP have been identified, such as platelet-derived growth factor, basic fibroblast growth factor/epidermal growth factor, histones, and high-molecular-weight kininogen. FSAP has also shown to induce DNA released from dead cells. Given its propensity for autoproteolysis and degradation, studies on the activation and regulation of FSAP are difficult to perform. Recent animal studies suggest a role of FSAP in the pathogenesis of arteriosclerosis, vascular integrity and probably also in the regulation of coagulation initiation. This review will focus on the biochemical properties of FSAP, regulation of FSAP activation, and finally its role in vascular disease and acute systemic inflammatory diseases, such as sepsis.

peripheral vascular disease,hematology
Tissue Factor in Tumor Microenvironment: a Systematic Review

Xiao Han,Bo Guo,Yongsheng Li,Bo Zhu

DOI: https://doi.org/10.1186/s13045-014-0054-8

IF: 28.5

2014-01-01

Journal of Hematology & Oncology

Abstract:The aberrant hemostasis is a common manifestation of cancer, and venous thromboembolism (VTE) is the second leading cause of cancer patients’ mortality. Tissue factor (TF), comprising of a 47-kDa transmembrane protein that presents in subendothelial tissues and leukocytes and a soluble isoform, have distinct roles in the initiation of extrinsic coagulation cascade and thrombosis. Laboratory and clinical evidence showed the deviant expression of TF in several cancer systems and its tumor-promoting effects. TF contributes to myeloid cell recruitment in tumor stroma, thereby remodeling of tumor microenvironment. Additionally, the number of TF-positive-microparticles (TF+MP) from tumor origins correlates with the VTE rates in cancer patients. In this review, we summarize our current understanding of the TF regulation and roles in tumor progression and clinical complications.
Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis

Giovanni Cimmino,Plinio Cirillo

DOI: https://doi.org/10.21037/cdt.2018.10.14

Abstract:For many years, the attention on tissue factor (TF) in human pathophysiology has been limited to its role as initiator of extrinsic coagulation pathway. Moreover, it was described as a glycoprotein located in several tissue including vascular wall and atherosclerotic plaque. However, in the last two decades, the discovery that TF circulates in the blood as cell-associated protein, microparticles (MPs) bound and as soluble form, is changing this old vessel-wall TF dogma. Moreover, it has been reported that TF is expressed by different cell types, even T lymphocytes and platelets, and different pathological conditions, such as acute and chronic inflammatory status, and cancer, may enhance its expression and activity. Thus, recent advances in the biology of TF have clearly indicated that beyond its known effects on blood coagulation, it is a "true surface receptor" involved in many intracellular signaling, cell-survival, gene and protein expression, proliferation, angiogenesis and tumor metastasis. Finally, therapeutic modulation of TF expression and/or activity has been tested with controversial results. This report, starting from the old point of view about TF as initiator of extrinsic coagulation pathway, briefly illustrates the more recent concepts about TF and thrombosis and finally gives an overview about its role beyond thrombosis and haemostasis focusing on the different intracellular mechanisms triggered by its activation and potentially involved in atherosclerosis.
Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis

Yohei Hisada,Nigel Mackman

DOI: https://doi.org/10.1055/s-0039-1687894

2019-05-16

Seminars in Thrombosis and Hemostasis

Abstract:Abstract There is a strong relationship between tissue factor (TF) and cancer. Many cancer cells express high levels of both full-length TF and alternatively spliced (as) TF. TF expression in cancer is associated with poor prognosis. In this review, the authors summarize the regulation of TF expression in cancer cells and the roles of TF and asTF in tumor growth and metastasis. A variety of different signaling pathways, transcription factors and micro ribonucleic acids regulate TF gene expression in cancer cells. The TF/factor VIIa complex enhances tumor growth by activating protease-activated receptor 2 signaling and by increasing the expression of angiogenic factors, such as vascular endothelial growth factor. AsTF increases tumor growth by enhancing integrin β1 signaling. TF and asTF also contribute to metastasis via multiple thrombin-dependent and independent mechanisms that include protecting tumor cells from natural killer cells. Finally, a novel anticancer therapy is using tumor TF as a target to deliver cytotoxic drugs to the tumor. TF may be useful in diagnosis, prognosis, and treatment of cancer.

peripheral vascular disease,hematology
Soluble Tissue Factor Has Unique Angiogenic Activities That Selectively Promote Migration and Differentiation but Not Proliferation of Endothelial Cells

Yingbo He,Guodong Chang,Shunli Zhan,Xiaomin Song,Xiaofeng Wang,Yongzhang Luo

DOI: https://doi.org/10.1016/j.bbrc.2008.03.133

IF: 3.1

2008-01-01

Biochemical and Biophysical Research Communications

Abstract:The level of circulating tissue factor (TF) is up-regulated in human angiogenesis-related malignancies. However, whether circulating TF has angiogenic activities has not been determined. Soluble TF (sTF) is the main domain of circulating TF. Here, using cell migration, wound healing, and tubule formation assays, human recombinant sTF was found to significantly promote the migration and differentiation of endothelial cells. The stress fiber formation and rearrangement induced by sTF observed through immunofluorescence microscope may be responsible for the stimulatory migration effect of sTF. Nevertheless, sTF had no effects on endothelial cell proliferation. Interestingly, sTF can be internalized by endothelial cells, which implies a novel mechanism for sTF in angiogenesis. These results suggest that sTF has unique angiogenic activities and may serve as a potential therapeutic target to treat diseases associated with angiogenesis such as cancer and rheumatoid arthritis.

Does Tissue Factor Participate In Angiogenesis?

Tissue factor (:Factor VIIa) in the heart and vasculature: More than an envelope

Structure–Function Relationship of the Interaction between Tissue Factor and Factor VIIa

Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis

Tissue factor pathway inhibitor – cofactor-dependent regulation of the initiation of coagulation

Tissue Factor and Tissue Factor Pathway Inhibitor in Coronary Atherosclerotic Plaque

[Tissue factor in acute coronary syndromes]

Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets

The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans

Tissue factor at the crossroad of coagulation and cell signaling

Tissue factor in atherosclerosis and atherothrombosis

Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy

Activated Factor VII-Antithrombin Complex, a Biomarker of Tissue Factor-Related Pathways in Different Clinical Settings: A Narrative Review from Cardiovascular Diseases to Cancer

Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?

Formation Of Tissue Factor-Factor Viia-Factor Xa Complex Promotes Cellular Signaling And Migration Of Human Breast Cancer Cells

Progression of tissue factor in the malignant tumor

Factor VII-Activating Protease: Hemostatic Protein or Immune Regulator?

Tissue Factor in Tumor Microenvironment: a Systematic Review

Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis

Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis

Soluble Tissue Factor Has Unique Angiogenic Activities That Selectively Promote Migration and Differentiation but Not Proliferation of Endothelial Cells